A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia
Brief description of study
The purpose of this research is to test an experimental drug CVL-562 as a possible treatment for early-course schizophrenia, schizoaffective disorder or related psychotic disorder.
This study will test whether CVL-562 can help thinking and memory in people with schizophrenia.
Detailed description of study
The study involves 7 in-person visits, including an initial intake visit, 5 scan visits, and 1 follow up visit, as well as a brief phone check in 1 month after completion of the study. An investigational medication is taken prior to the scan on each of the 5 scan visits. In addition to medical assessments, subjects will participate in clinical interviews, cognitive assessments, and MRIs. Total compensation is up to $2,910.
Additional Information
Visit our website: https://clinicaltrials.gov/ct2/show/NCT04457310?term=PF-06412562&cond=Schizophrenia&draw=2&rank=2
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
schizophrenia,schizoaffective disorder,related psychotic disorders,schizophreniform disorder,psychosis
-
Age: Between 18 Years - 45 Years
-
Gender: All
To be eligible, study participants must meet DSM-5 criteria for a primary non-affective psychotic disorder (schizophrenia, schizoaffective, or schizophreniform) with onset of psychosis within the past 10 years. Psychiatric symptoms and treatment must be stable (no active/remarkable SI/HI, no anticipated need to change medications during study). Patients must not have had an active moderate/severe substance use disorder (except nicotine). Patients may be unmedicated, but only certain antipsychotics are allowed (olanzapine, clozapine, ziprasidone or asenapine are exclusionary), and certain other psychoactive medications are not allowed (stimulants or other current pharmacotherapy for ADHD, medical cannabis, anticonvulsants except when used as mood stabilizers).
Updated on
05 Jan 2024.
Study ID: 842909
